New method for delivering immune drugs to treat Type 1 diabetes
New way in delivering immunomodulatory drugs in T1D
This study is exploring a new way to deliver diabetes medications directly to the parts of the body that need them most, which could help people with Type 1 diabetes feel better while reducing side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11011423 on NIH RePORTER |
What this research studies
This research focuses on developing a targeted delivery system for immunomodulatory drugs aimed at treating Type 1 diabetes (T1D). By utilizing polymeric nanoparticles, the study seeks to enhance the delivery of these drugs directly to affected tissues, minimizing side effects and improving efficacy. The approach involves understanding how autoreactive T cells are activated in the pancreatic lymph nodes and ensuring that the therapeutic agents reach these specific sites effectively. This innovative method aims to provide a more effective treatment option for individuals suffering from T1D.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Type 1 diabetes who may benefit from improved immunomodulatory therapies.
Not a fit: Patients with Type 2 diabetes or those who do not have autoimmune diabetes may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatments for patients with Type 1 diabetes.
How similar studies have performed: While targeted nanomedicine is a promising approach, this specific method of delivering immune therapeutics for T1D is relatively novel and has not been extensively tested in prior studies.
Where this research is happening
Boston, United States
- Brigham and Women's Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Abdi, Reza — Brigham and Women's Hospital
- Study coordinator: Abdi, Reza
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.